Transgene SA 2024 IR
The report highlights Transgene's progress in 2024, notably achieving clinical proof of principle for its individualized cancer vaccine, TG4050, with all treated patients remaining disease-free after a median follow-up of 24.1 months. Based on these results, the company initiated the randomized Phase II part of the study in the second quarter of 2024. Additionally, Transgene reported positive preliminary data for its oncolytic virus BT-001 and completed enrollment for the Phase I trial of TG6050. On the sustainability front, the company conducted its second carbon assessment, showing total emissions of 2,381 metric tons of CO2e for 2023, and continued its commitment to reducing its environmental footprint.
Company: Transgene SA
Sector: Health Care
Country: France
Year: 2024
Type: IR
Pages: 256
Transgene SA
Universal Registration Document
The report highlights Transgene's progress in 2024, notably achieving clinical proof of principle for its individualized cancer vaccine, TG4050, with all treated patients remaining disease-free after a median follow-up of 24.1 months. Based on these results, the company initiated the randomized Phase II part of the study in the second quarter of 2024. Additionally, Transgene reported positive preliminary data for its oncolytic virus BT-001 and completed enrollment for the Phase I trial of TG6050. On the sustainability front, the company conducted its second carbon assessment, showing total emissions of 2,381 metric tons of CO2e for 2023, and continued its commitment to reducing its environmental footprint.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Women in Management
Employees